Drugs / Amniotic Fluid
Amniotic Fluid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT03583151 | May → Dec 2018 | tenosynovitis | J&M Shuler | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT04281004 Comparator | Jul 2020 → Jan 2023 | — | University of Utah | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amniotic fluid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03583151 ↗ |
| Known as | AFED | “One drop (0.25 mL) of Amniotic Fluid Eye Drops (AFED) in each eye four times daily for seven days” NCT04281004 ↗ |
| Known as | Amniotic Fluid Eye Drops | “One drop (0.25 mL) of Amniotic Fluid Eye Drops (AFED) in each eye four times daily for seven days” NCT04281004 ↗ |
| Known as | pAF | “Purified amniotic fluid (pAF) contains anti-inflammatory, anti-microbial and regenerative factors similar to solid amniotic membrane.” NCT04281004 ↗ |